Betul Oran1, Daniel J Weisdorf. 1. Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis, Minnesota, USA. oranx002@umn.edu
Abstract
PURPOSE OF REVIEW: The optimal postremission therapy of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain. This review summarizes the recent developments in the clinical research and therapeutic applications defining the role of allogeneic hematopoietic stem cell transplantation (allo-HCT) in CR1. RECENT FINDINGS: Molecular markers in combinations with cytogenetics have improved the risk stratification and informed decision-making in patients with AML in CR1. In parallel, several important advances in the transplant field, such as better supportive care, improved transplant technology, increased availability of alternative donors, and reduced-intensity conditioning, have improved the safety as well as access of allo-HCT for a larger number of patients. SUMMARY: The progress in risk stratification and in transplant technology dictate that early donor identification search should be initiated for all eligible AML patients in CR1.
PURPOSE OF REVIEW: The optimal postremission therapy of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain. This review summarizes the recent developments in the clinical research and therapeutic applications defining the role of allogeneic hematopoietic stem cell transplantation (allo-HCT) in CR1. RECENT FINDINGS: Molecular markers in combinations with cytogenetics have improved the risk stratification and informed decision-making in patients with AML in CR1. In parallel, several important advances in the transplant field, such as better supportive care, improved transplant technology, increased availability of alternative donors, and reduced-intensity conditioning, have improved the safety as well as access of allo-HCT for a larger number of patients. SUMMARY: The progress in risk stratification and in transplant technology dictate that early donor identification search should be initiated for all eligible AMLpatients in CR1.
Authors: Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Tamara Vukosavljevic; Peter Paschka; Susan P Whitman; Christian Langer; Claudia D Baldus; Chang-Gong Liu; Amy S Ruppert; Bayard L Powell; Andrew J Carroll; Michael A Caligiuri; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2008-09-22 Impact factor: 44.544
Authors: Jan J Cornelissen; Wim L J van Putten; Leo F Verdonck; Matthias Theobald; Emanuel Jacky; Simon M G Daenen; Marinus van Marwijk Kooy; Pierre Wijermans; Harry Schouten; Peter C Huijgens; Hans van der Lelie; Martin Fey; Augustin Ferrant; Johan Maertens; Alois Gratwohl; Bob Lowenberg Journal: Blood Date: 2007-01-09 Impact factor: 22.113
Authors: Frederik Damm; Michael Heuser; Michael Morgan; Katharina Wagner; Kerstin Görlich; Anika Grosshennig; Iyas Hamwi; Felicitas Thol; Ewa Surdziel; Walter Fiedler; Michael Lübbert; Lothar Kanz; Christoph Reuter; Gerhard Heil; Ruud Delwel; Bob Löwenberg; Peter J M Valk; Jürgen Krauter; Arnold Ganser Journal: Blood Date: 2011-03-03 Impact factor: 22.113
Authors: Sebastian Schwind; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Kelsi B Holland; Dean Margeson; Heiko Becker; Susan P Whitman; Yue-Zhong Wu; Klaus H Metzeler; Bayard L Powell; Jonathan E Kolitz; Thomas H Carter; Joseph O Moore; Maria R Baer; Andrew J Carroll; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield Journal: Blood Date: 2010-09-14 Impact factor: 22.113
Authors: Gunnar Juliusson; Karin Karlsson; Vladimir Lj Lazarevic; Anders Wahlin; Mats Brune; Petar Antunovic; Asa Derolf; Hans Hägglund; Holger Karbach; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Helene Hallböök; Martin Höglund Journal: Cancer Date: 2011-03-08 Impact factor: 6.860
Authors: Jacob M Rowe; Donna Neuberg; William Friedenberg; John M Bennett; Elisabeth Paietta; Adel Z Makary; Jane L Liesveld; Camille N Abboud; Gordon Dewald; F Ann Hayes; Martin S Tallman; Peter H Wiernik Journal: Blood Date: 2003-09-25 Impact factor: 22.113
Authors: Sanne Lugthart; Ellen van Drunen; Yvette van Norden; Antoinette van Hoven; Claudia A J Erpelinck; Peter J M Valk; H Berna Beverloo; Bob Löwenberg; Ruud Delwel Journal: Blood Date: 2008-02-13 Impact factor: 22.113
Authors: Christian Langer; Guido Marcucci; Kelsi B Holland; Michael D Radmacher; Kati Maharry; Peter Paschka; Susan P Whitman; Krzysztof Mrózek; Claudia D Baldus; Ravi Vij; Bayard L Powell; Andrew J Carroll; Jonathan E Kolitz; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544